Skip to content

Comparison of intraoperative intravenous anesthetic agents (propofol and remimazolam) in patients with lung cancer :prospective cohort study

Comparison of intraoperative intravenous anesthetic agents (propofol and remimazolam) in patients with lung cancer: prospective cohort study - Comparison of intravenous anesthetic agents in patients with lung cancer: prospective cohort study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
JPRN
Registry ID
JPRN-UMIN000044009
Enrollment
150
Registered
2021-04-25
Start date
2021-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer patients

Interventions

None listed

Sponsors

Department of anesthesiology and pain medicine, Juntendo University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Operate on one side of the lung. Patients diagnosed with primary and metastatic lung cancer. Hospitalized patients. Those who, after receiving sufficient explanation and understanding, have given written consent of their own free will to participate in this research.

Exclusion criteria

Exclusion criteria: Patients whose consent was not obtained. Patients who are taking immunosuppressive drugs or steroids. Patients who have already received chemoradiation therapy. Simultaneous bilateral surgery. Patients with autoimmune diseases such as collagen diseases. Cardiac disease of NYHA III degree or higher. Respiratory dysfunction with a VC or FEV1 of less than 50%. Pulmonary hypertension with mean pulmonary artery pressure of 30 mmHg or more. Highly obese patients with BMI greater than 30. Severe hepatic or renal dysfunction. Patients with allergy to propofol or benzodiazepine anesthetics. Other patients who are judged by the principal investigator to be inappropriate as research subjects.

Design outcomes

Primary

MeasureTime frame
Partial pressure of arterial blood oxygen during one-lung ventilation

Secondary

MeasureTime frame
Evaluation of awakening Immunosuppressive effect

Countries

Japan

Contacts

Public ContactTsukasa Kochiyama

Juntendo University Department of anesthesiology and pain medicine

tkouchi@juntendo.ac.jp0338133111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026